Aerpio Therapeutics Garners $27,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c531f160-55a7-4c4b-8180-d12d692b4e71&Preview=1 - Date
9/1/2012 - Company Name
Aerpio Therapeutics - Mailing Address
9987 Carver Road Cincinnati, OH 45242 - Company Description
Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. - Website
http://www.aerpio.com - Transaction Type
Venture Equity - Transaction Amount
$27,000,000 - Transaction Round
Series A - Proceeds Purposes
The proceeds will support ongoing development of Aerpio’s pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema (DME). - M&A Terms
- Venture Investor
Novartis BioVenture Fund - Venture Investor
Venture Investors - Venture Investor
Triathlon Medical Ventures - Venture Investor
Kearny Venture Partners - Venture Investor
Athenian Venture Partners - Venture Investor
AgeChem Venture Fund
